COMPANY PROFILE

Gilead Sciences

Explore full profile

Biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases

Foster City, United StatesFounded 1987Biotech & Life Sciences

Valuation $202B Market cap · 2026

Revenue $31B Latest reported FY

EBITDA $7.86B Latest reported FY

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines. The company primarily serves patients and healthcare providers, aiming to address unmet medical needs in areas such as HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead operates in the global healthcare market, with a significant presence in both developed and emerging markets.

The company's business model revolves around extensive research and development (R&D) to create new therapies, followed by the commercialization of these products. Gilead invests heavily in R&D to maintain a robust pipeline of potential new treatments. Once a drug is developed and approved by regulatory authorities, it is marketed and sold to healthcare providers, hospitals, and pharmacies.

Gilead generates revenue primarily through the sale of its pharmaceutical products. The company also engages in strategic partnerships and collaborations to enhance its product offerings and expand its market reach. For instance, Gilead has partnered with SAP Ariba to streamline its procurement and supply chain processes, ensuring responsible sourcing and sustainable manufacturing practices.

In addition to its commercial activities, Gilead is committed to improving health equity and access to care. The company partners with communities worldwide to remove barriers to healthcare and make its medicines available to those who need them most. Initiatives like the COMPASS Initiative, HepConnect, and HIV Age Positively are examples of Gilead's efforts to drive positive change and create a healthier world for all people.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1987
Headquarters: Foster City, United States
Listing: IPO 1992
Employees: 14,891
Open positions: 448
Dealroom signal: 69.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Horizon Europe
Business model: Manufacturing
Client focus: b2b, b2c
Investment activity: 63 companies, latest Jun 2026
Capital deployed: $1.9B
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITY✓Other financing	Sep 2026	$3.4M	—	AXQ Capital	↗
POST IPO EQUITY✓Other financing	Jun 2026	$0	—	Archer Investment	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$31B	+4.3%	$7.9B	25.6%	−$4.3B	-13.9%	$5.7B
2025	$29B	+2.4%	$16B	54.2%	$8.5B	28.9%	$5.7B
2024	$29B	+6%	$11B	36.9%	$480M	1.7%	$5.7B
2023	$27B	-0.6%	$12B	43.2%			$5.7B
2022	$27B	-0.1%	$10B	38.1%
2021	$27B	+10.6%	$9.5B	34.6%
2020	$25B	—	$8.5B	34.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Gilead Sciences website traffic

Latest recorded traffic for Gilead Sciences is 640K monthly website visits, down 11.1% over the last three months.

Latest monthly visits640K 3-month web change-11.1%

Monthly website visitsMar 2017–Mar 2021

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Assoc Director, Medical AffairsHong Kong, China, Eastern Asia, Asia · Other · Oct 6, 2026 Manager, Supply Chain (Global Trade Compliance)- USA & CanadaFoster City, California, United States, Northern America, Americas · Logistics · Oct 6, 2026 Exec Director, PBC MarketingFoster City, California, United States, Northern America, Americas · Marketing & Communication · Oct 6, 2026 Assoc Clinical Development DirectorFoster City, California, United States, Northern America, Americas · Other · Oct 5, 2026 Director, RWE Analysis and Programming - Medial Affairs ResearchFoster City, California, United States, Northern America, Americas · Other · Oct 5, 2026 Device Engineer IIFoster City, California, United States, Northern America, Americas · Android Development · Oct 5, 2026 Enterprise Technology Lead, Senior ManagerEl Segundo, California, United States, Northern America, Americas · Business Development · Oct 3, 2026 Prevention Specialist, HIV Prevention -- Chicago WestChicago, Illinois, United States, Northern America, Americas · Other · Oct 3, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRProtavioBiomarker Discovery \| Cambridge \| Protavio Ltd	Athens, Greece	Operational	8	—	—
ANAndaman7Patient-centric personal health record and intermediation platform	Seraing, Belgium	Operational
PFPierre FabrePioneering allogeneic cell therapies for oncology and rare diseases with a focus on unmet patient needs	Toulouse, France	Operational
SBSwedish Orphan BiovitrumEngages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals	Solna kommun, Sweden	Acquired
MCMerck & Co.Merck develops and produces medicines, vaccines, biologic therapies and animal health products	Rahway, United States	Operational
SIScinai ImmunotherapeuticsThe leading #UniversalFluVaccine candidate: Designed for multi-season multi-strain protection from seasonal & pandemic influenza; Phase 3 trial. (NASDAQ: $BVXV)	Jerusalem, Israel	Operational
IPIceni PharmaceuticalsDeveloping cancer therapies by repurposing and reformulating existing drugs for new indications, reducing costs and risks	Roslin, United Kingdom	Operational
MBMitra bioNon-invasive diagnostics for skincare and therapeutics development	London, United Kingdom	Operational